Siga Technologies, Inc.

Corvallis, OR 97333

Market Performance

NASDAQ: SIGA
Market Cap $379 Million
52 Week High $5.24
52 Week Low $1.90

SBIR Award Summary

Total Number of Awards 30
Total Value of Awards $29.2MM
First Award Date 07/01/99
Most Recent Award Date 09/01/11

Key Personnel

Last Name Name Awards Contact
Geller Bruce L Geller 1
Burgess Susan K. Burgess 1
Hruby Dennis E. Hruby 14
Jones C H Jones 2
Jordan Robert Jordan 4
Amberg Sean M Amberg 3
Grosenbach Douglas W. Grosenbach 5

30 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-134
Budget: 09/01/11 - 02/28/13

DESCRIPTION (provided by applicant): Naturally occurring smallpox has been eradicated but remains a credible threat to the security of the United States due to its potential use as an agent of terror or biowarfare. Given that approximately 25% of the population is contraindicated to receive the vaccine due to direct risk of adverse events or the...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-134
Budget: 09/01/10 - 08/31/11

DESCRIPTION (provided by applicant): Naturally occurring smallpox has been eradicated but remains a credible threat to the security of the United States due to its potential use as an agent of terror or biowarfare. Given that approximately 25% of the population is contraindicated to receive the vaccine due to direct risk of adverse events or the...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-134
Budget: 09/04/09 - 08/31/10

DESCRIPTION (provided by applicant): Naturally occurring smallpox has been eradicated but remains a credible threat to the security of the United States due to its potential use as an agent of terror or biowarfare. Given that approximately 25% of the population is contraindicated to receive the vaccine due to direct risk of adverse events or the...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-134
Budget: 08/01/09 - 07/31/10

DESCRIPTION (provided by applicant): There is an urgent need for new antivirals for both treatment and control of dengue virus, given that over 50 million people are infected worldwide with dengue every year, including 500,000 cases of the more severe form of the disease, dengue hemorrhagic fever (DHF) and there are no approved vaccines or antiv...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 09/01/08 - 05/31/10

DESCRIPTION (provided by applicant): The focus of this proposal is to develop a safe, effective subunit vaccine delivery system. To accomplish this, we will utilize our bacterial commensal vector (BCV) technology. BCV uses the Gram-positive commensal bacteria, Streptococcus gordonii, to express heterologous antigens of interest on its external ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAS-02-149
Budget: 09/01/08 - 08/31/09

DESCRIPTION (provided by applicant): Hemorrhagic fever viruses are of serious worldwide health concern as well as potential biological weapons. Lassa fever virus in particular annually infects several hundred thousand individuals in West Africa, and the export of this pathogen outside of this region, either intentionally or unintentionally, pres...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 08/18/08 - 07/31/09

DESCRIPTION (provided by applicant): There is an urgent need for new antivirals for both treatment and control of dengue virus, given that over 50 million people are infected worldwide with dengue every year, including 500,000 cases of the more severe form of the disease, dengue hemorrhagic fever (DHF) and there are no approved vaccines or antiv...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAS-02-149
Budget: 08/01/08 - 01/31/10

DESCRIPTION (provided by applicant): Concern over the use of variola virus as a biological weapon has prompted interest in development of small molecule therapeutics for smallpox. Variola virus is highly transmissible and causes severe disease with high mortality rates. Currently, there is no FDA-approved drug for prevention or treatment of smal...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 08/01/08 - 07/31/09

DESCRIPTION (provided by applicant): The renewed threat of smallpox as a bioweapon and the emerging zoonotic threat of monkeypox highlight the need for effective poxvirus countermeasures. Use of the smallpox vaccine poses a serious health risk, especially for the immunocompromised, or those with eczema/atopic dermatitis. It is our long-term goal...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 09/15/07 - 08/31/08

DESCRIPTION (provided by applicant): The focus of this proposal is to develop a safe, effective subunit vaccine delivery system. To accomplish this, we will utilize our bacterial commensal vector (BCV) technology. BCV uses the Gram-positive commensal bacteria, Streptococcus gordonii, to express heterologous antigens of interest on its external ...

Load More